Technical bounce back on cardsDR. REDDY S LABORATORIESNSE:DRREDDYramkdlrRevenue: ₹8,545 crore (~11% YoY increase) Net Profit (PAT): ₹1,418 crore (~2% YoY growth) North America generics revenue declined ~11% to ₹3,412 crore due to pricing pressures, while Europe surged 142% YoY Consensus estimates (SimplyWall.st): Average target at ₹1,289, with bullish/bearish range ₹1,660–₹990. Growth forecast modest (~2.9% revenue CAGR through 2026) — down from 13% historical average Despite milestones in revenue, margins remain under pressure from global competition For long-term investors: A conservative growth stock with moderate dividend income—best suited for those seeking stability with exposure to generics in key markets. For traders or momentum players: Watch India- and Europe-driven growth and pipeline developments. U.S. competition remains a major swing factor.